Cardiovascular Systems, Inc. (CSII)
Stock Price:
$31.11 USD
0.20 (0.65%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.23B |
| Revenue (ttm) |
236.54M |
| Net Income (ttm) |
-10.60M |
| Shares Out |
39.50M |
| EPS (ttm) |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$31.11 |
| Previous Close |
$30.91 |
| Change ($) |
0.20 |
| Change (%) |
0.65% |
| Day's Open |
30.62 |
| Day's Range |
30.62 - 31.74 |
| Day's Volume |
187,787 |
| 52-Week Range |
26.00 - 55.22 |
More Stats
| Market Cap |
1.23B |
| Enterprise Value |
1.14B |
| Earnings Date (est) |
Oct 21, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.50M |
| Float |
33.99M |
| EPS (basic) |
-0.31 |
| EPS (diluted) |
-0.80 |
| FCF / Share |
0.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
0.11% |
| Payout Ratio |
n/a |
| Shares Short |
1.29M |
| Short Ratio |
3.15 |
| Short % of Float |
4.19% |
| Beta |
1.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
904.28 |
| PS Ratio |
5.20 |
| PB Ratio |
8.48 |
| Revenue |
236.54M |
| Operating Income |
-10.79M |
| Net Income |
-10.60M |
| Free Cash Flow |
1.36M |
| Net Cash |
86.39M |
| Net Cash / Share |
2.19 |
| Gross Margin |
79.39% |
| Operating Margin |
-4.56% |
| Profit Margin |
-4.00% |
| FCF Margin |
0.57% |
| ROA |
-6.00% |
| ROE |
-13.07% |
| ROIC |
-7.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
7 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
1 |
| Sell |
0 |
Price Target
$43.78*
(40.73% upside)
Low
38.0
Current: $31.11
High
50.0
Target: 43.78
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 248 | 217 | 205 | 178 | 182 | 137 | 104 | 82.49 | 78.78 | 64.83 |
| Revenue Growth | 14.27% | 5.92% | 15% | -1.85% | 32.89% | 31.49% | 25.95% | 4.71% | 21.52% | - |
| Gross Profit | 200 | 178 | 165 | 143 | 142 | 106 | 79.52 | 63.27 | 62.50 | 49.83 |
| Operating Income | -0.83 | 2.23 | -1.54 | -56.08 | -32.64 | -33.49 | -22.42 | -14.47 | -8.81 | -22.90 |
| Net Income | -0.26 | 1.71 | -1.79 | -56.02 | -32.82 | -35.29 | -24.04 | -16.79 | -11.13 | -23.90 |
| Shares Outstanding | 33.54 | 33.15 | 32.37 | 32.54 | 31.55 | 28.30 | 21.69 | 18.04 | 15.92 | 14.75 |
| Earnings Per Share | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 |
| Operating Cash Flow | 10.21 | 9.67 | 19.59 | -23.58 | -22.36 | -26.84 | -10.77 | -11.34 | -8.36 | -13.57 |
| Capital Expenditures | -2.67 | -1.96 | -0.98 | -3.82 | -20.33 | -12.72 | -1.67 | -0.44 | -1.08 | -0.79 |
| Free Cash Flow | 7.54 | 7.72 | 18.61 | -27.40 | -42.68 | -39.56 | -12.44 | -11.78 | -9.44 | -14.36 |
| Cash & Equivalents | 123 | 117 | 109 | 61.32 | 85.72 | 127 | 67.90 | 35.53 | 21.16 | 23.72 |
| Total Debt | 20.97 | 21.06 | 21.10 | - | - | 2.40 | 12.57 | 17.52 | 12.14 | 11.29 |
| Net Cash / Debt | 102 | 95.74 | 87.52 | 61.32 | 85.72 | 124 | 55.33 | 18.01 | 9.02 | 12.43 |
| Assets | 219 | 203 | 194 | 142 | 171 | 182 | 96.90 | 63.12 | 46.76 | 42.72 |
| Liabilities | 70.63 | 68.88 | 75.55 | 41.51 | 31.89 | 29.85 | 30.07 | 30.94 | 25.12 | 25.01 |
| Book Value | 148 | 134 | 118 | 101 | 139 | 152 | 66.83 | 32.19 | 21.64 | 17.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cardiovascular Systems, Inc. |
| Country |
United States |
| CEO |
Scott R. Ward |
Stock Information
| Ticker Symbol |
CSII |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: CSII |
| IPO Date |
February 26, 2009 |
Description
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary OAS, a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.